Core Insights - Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections [1][3] - Esther Rajavelu, the Interim President and CEO of Spero, will present at the TD Cowen 45 Annual Health Care Conference in Boston from March 3 to 5, 2025 [1][2] Company Overview - Spero Therapeutics is headquartered in Cambridge, Massachusetts, and is engaged in identifying and developing novel treatments for rare diseases and MDR bacterial infections [3] - The company provides an opportunity for one-on-one meetings during the conference, indicating a proactive approach to investor relations [1][2] Event Details - The company presentation is scheduled for March 5, 2025, at 3:10 PM ET [2] - A webcast of the presentation will be available on Spero Therapeutics' website, with a replay accessible after the event [2]
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference